White House confirms Section 232 pharma investigation has resulted in 100% tariffs on some brand drugsnews2025-09-30T13:55:36+00:00September 30th, 2025|Endpoints News|
Crystalys lands $205M to bring gout drug first marketed in Japan to the US and Europenews2025-09-30T12:00:17+00:00September 30th, 2025|Endpoints News|
Metsera’s new obesity data create side effect and efficacy questions for Pfizer to answernews2025-09-30T11:31:58+00:00September 30th, 2025|Endpoints News|
AnaptysBio plans to split its pipeline from its royalty assets into two publicly traded companiesnews2025-09-30T11:29:18+00:00September 30th, 2025|Endpoints News|
Opus says gene therapy for ultra-rare disease boosted vision in teensnews2025-09-30T11:00:13+00:00September 30th, 2025|Endpoints News|
Star gets $125M Series D as it begins Phase 3 in bleeding disordersnews2025-09-30T10:30:56+00:00September 30th, 2025|Endpoints News|
CDER director says FDA to take ‘close look’ at use of surrogate endpointsnews2025-09-29T19:52:17+00:00September 29th, 2025|Endpoints News|
GSK CEO Emma Walmsley on her exit, running the company and morenews2025-09-29T18:00:31+00:00September 29th, 2025|Endpoints News|
Genmab CEO on his yearslong interest in Merusnews2025-09-29T17:00:00+00:00September 29th, 2025|Endpoints News|
White House deadline brings flurry of pharma price cutdownsnews2025-09-29T16:20:56+00:00September 29th, 2025|Endpoints News|
